Navigation Links
Common transplant drug inhibits breast cancer growth, UNC laboratory study shows
Date:5/26/2011

Tacrolimus, a drug that is commonly used to prevent organ transplantation rejection, inhibits breast cancer growth in pre-clinical studies. The finding from UNC scientists was reported in the May 26th PLoS ONE.

Nancy Klauber-DeMore, MD, associate professor of surgery, said, " We now have a rationale for performing human clinical trials to determine if Tacrolimus reduces breast cancer growth in humans. Since Tacrolimus is already an FDA-approved drug, the safety and toxicity profile is known, which means that Tacrolimus could potentially go directly into a later stage clinical trial."

Klauber-DeMore is a member of UNC Lineberger Comprehensive Cancer Center and co-founder and Chief Scientific Officer of Enci Therapeutics, Inc., a UNC spin-off biotech company.

Tacrolimus is used to prevent rejection (when a person's immune system attacks of a transplanted organ by the immune system of a person receiving the organ) in people who have received kidney, liver, or heart transplants. Tacrolimus is in a class of medications called immunosuppressants. It works by decreasing the activity of the immune system to prevent it from attacking the transplanted organ. Tacrolimus does this by binding to and inactivating a protein called calcineurin in immune cells.

Although preventing organ transplant rejection and inhibiting cancer growth may seem unrelated, the team realized that activating calcineurin is a common pathway that stimulates both the immune system and the growth of new blood vessels to tumors. Blocking blood vessel growth to tumors is a therapeutic strategy to inhibit tumor growth.

Klauber-DeMore's group had previously discovered that a protein called SFRP2 stimulates blood vessel growth and is expressed in human breast cancers. While investigating the mechanism through which SFRP2 stimulates blood vessel growth, they found that SFRP2 activates calcineurin in blood vessel cells. Based on this mechanism, Klauber-DeMore thought that Tacrolimus might also bind to and inactivate calcineurin in blood vessel cells, thereby blocking new blood vessel growth to tumors. The team tested this theory in a pre-clinical breast tumor model and found that orally administered Tacrolimus inhibited breast tumor growth rate by over 70 percent.

Klauber-DeMore said, "This data is encouraging, but we don't know yet whether Tacrolimus will inhibit breast cancer growth in humans. However, this pre-clinical study provides a reasoning for the next step, which will be to perform a clinical trial using Tacrolimus in patients with breast cancer."


'/>"/>

Contact: Dianne Shaw
dgs@med.unc.edu
919-966-7834
University of North Carolina School of Medicine
Source:Eurekalert

Related medicine news :

1. Adapting to clogged airways makes common pathogen resist powerful drugs
2. A common cholesterol drug fights cataracts, too
3. U.S. National Guard Connects Nationwide with Desktop Alert's Command and Control Mass Notification Systems and Common Alerting Protocol (CAP)
4. US21, Inc. is Granted a Wholesale Distributor Permit from the Commonwealth of Virginia Board of Pharmacy
5. New therapeutic target for most common solid cancer in childhood?
6. Migraine More Common in Women with MS
7. Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis
8. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
9. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
10. Common osteoporosis drugs are associated with a decrease in risk of breast cancer
11. Commonwealth Leverage Group and Helium Interactive Form HIE Go-To-Market Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... ... September 26, 2017 , ... “Childhood Memories of a Virginia Wanderer”: ... and help them relive their own youth. “Childhood Memories of a Virginia Wanderer” is ... US Navy for nine years. He received his BS from Idaho State University ...
(Date:9/26/2017)... ... ... story of the author and the exciting times this adventurer has lived through. “The Tour ... and the subject of the book. , “Quickly slapping a large smile on my ... off as a part of the adventure tour, an “added bonus” story they would never ...
(Date:9/26/2017)... ... ... Ceebie”: a tool families can use to teach children about the love of God. ... a devoted follower of Jesus Chris who is married with one son. Originally from ... children but also to glorified God in everything he does.” --G.S. White , Published by ...
(Date:9/25/2017)... ... ... Your World Insurance Services, a long-time Redlands insurance and financial services firm, ... owner Stacy Boyle to give back to the many charitable organizations that help families ... school,” said Ms. Boyle. “My father passed away without life insurance, and my mother, ...
(Date:9/25/2017)... ... September 25, 2017 , ... Sensogram Technologies Inc. today ... detection smart watch. VitalBand provides elite level fall detection, automatically calls any ... help arrives quickly. Plus, it’s a fully functioning smart watch and activity ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)...  Medical professionals are expected to continuously ... their patients. Medical simulations offer clinicians the ... Simulation provides a safe method for teaching ... refine techniques and build confidence, without putting ... such as augmented reality, will now provide ...
(Date:9/5/2017)... another milestone in their continued growth and success of the company.  Xyntek has ... engagements regionally.  ... at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest office will support the ... In addition to Xyntek,s headquarters ...
(Date:9/1/2017)... Like Us ( https://explorerslikeus.com/ ) is embarking on "An American ... these experiences as part of Life Environments™, a new technology ... ... beats a walk, jog or simply playing in a garden ... next best thing when getting there isn’t possible. Life Environments™ ...
Breaking Medicine Technology: